Clinical Trial

Imprinting in Metabolic Diseases - Identifying Epigenetic Mechanisms in Human Gestational Diabetes Through Cell-free DNA

Study acronym: Epi_GDM
Recruiting
View on ClinicalTrials.gov →
Summary
This clinical trials aims to investigate the impact of parental metabolism during pregnancy on fetal epigenetic signatures. The metabolic profiles of both parents will be evaluated through a blood sample collected from the father and an oral glucose tolerance test administered to the pregnant mother. Additionally, epigenetic signatures will be assessed using parental blood samples. Fetal epigenetic signatures can be identified by analyzing fetal cell-free DNA that circulates in the mother's bloodstream.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-02-20; most recent amendment 2026-03-31.
Status change: Not Yet Recruiting → Recruiting 2026-03-19
Trial Details
NCT Number NCT07436195
Lead Sponsor University of Ulm
Conditions Gestational Diabetes Mellitus (GDM)
Enrollment 80 participants
Start Date 2026-03-30
Primary Completion 2028-03-01 (estimated)
Study Completion 2028-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-07